Bioventus Inc (BVS)
5.46
-0.12
(-2.15%)
USD |
NASDAQ |
Jun 25, 16:00
5.46
0.00 (0.00%)
After-Hours: 20:00
Bioventus Research and Development Expense (Annual): 13.45M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 13.45M |
| December 31, 2022 | 23.85M |
| December 31, 2021 | 19.04M |
| December 31, 2020 | 11.20M |
| December 31, 2019 | 11.06M |
| Date | Value |
|---|---|
| December 31, 2018 | 8.095M |
| December 31, 2015 | 14.75M |
| December 31, 2014 | 9.465M |
| December 31, 2013 | 10.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
11.06M
Minimum
2019
23.85M
Maximum
2022
15.72M
Average
13.45M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.31M |
| Retractable Technologies Inc | 0.5812M |
| Xtant Medical Holdings Inc | 1.336M |
| Asensus Surgical Inc | 37.02M |
| Catheter Precision Inc | 0.475M |